Loss of FAM46C promotes cell survival in myeloma

Yuan Xiao Zhu, Chang Xin Shi, Laura A. Bruins, Patrick Jedlowski, Xuewei Wang, K. Martin Kortüm, Moulun Luo, Jonathan M. Ahmann, Esteban D Braggio, Alexander Keith Stewart

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

FAM46C is one of the most recurrently mutated genes in multiple myeloma; however its role in disease pathogenesis has not been determined. Here we demonstrate that wild-type (WT) FAM46C overexpression induces substantial cytotoxicity in multiple myeloma cells. In contrast, FAM46C mutations found in multiple myeloma patients abrogate this cytotoxicity, indicating a survival advantage conferred by the FAM46C mutant phenotype. WT FAM46C overexpression downregulated IRF4, CEBPB, and MYC and upregulated immunoglobulin (Ig) light chain and HSPA5/BIP. Furthermore, pathway analysis suggests that enforced FAM46C expression activated the unfolded protein response pathway and induced mitochondrial dysfunction. CRISPR-mediated depletion of endogenous FAM46C enhanced multiple myeloma cell growth, decreased Ig light chain and HSPA5/BIP expression, activated ERK and antiapoptotic signaling, and conferred relative resistance to dexamethasone and lenalidomide treatments. Genes altered in FAM46C-depleted cells were enriched for signaling pathways regulating estrogen, glucocorticoid, B-cell receptor signaling, and ATM signaling. Together these results implicate FAM46C in myeloma cell growth and survival and identify FAM46C mutation as a contributor to myeloma pathogenesis and disease progression via perturbation in plasma cell differentiation and endoplasmic reticulum homeostasis.

Original languageEnglish (US)
Pages (from-to)4317-4327
Number of pages11
JournalCancer Research
Volume77
Issue number16
DOIs
StatePublished - Aug 15 2017

Fingerprint

Multiple Myeloma
Cell Survival
Immunoglobulin Light Chains
Clustered Regularly Interspaced Short Palindromic Repeats
Unfolded Protein Response
Mutation
Growth
Plasma Cells
Endoplasmic Reticulum
Dexamethasone
Glucocorticoids
Genes
Disease Progression
Cell Differentiation
Estrogens
Homeostasis
B-Lymphocytes
Down-Regulation
Phenotype
Survival

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Zhu, Y. X., Shi, C. X., Bruins, L. A., Jedlowski, P., Wang, X., Kortüm, K. M., ... Stewart, A. K. (2017). Loss of FAM46C promotes cell survival in myeloma. Cancer Research, 77(16), 4317-4327. https://doi.org/10.1158/0008-5472.CAN-16-3011

Loss of FAM46C promotes cell survival in myeloma. / Zhu, Yuan Xiao; Shi, Chang Xin; Bruins, Laura A.; Jedlowski, Patrick; Wang, Xuewei; Kortüm, K. Martin; Luo, Moulun; Ahmann, Jonathan M.; Braggio, Esteban D; Stewart, Alexander Keith.

In: Cancer Research, Vol. 77, No. 16, 15.08.2017, p. 4317-4327.

Research output: Contribution to journalArticle

Zhu, YX, Shi, CX, Bruins, LA, Jedlowski, P, Wang, X, Kortüm, KM, Luo, M, Ahmann, JM, Braggio, ED & Stewart, AK 2017, 'Loss of FAM46C promotes cell survival in myeloma', Cancer Research, vol. 77, no. 16, pp. 4317-4327. https://doi.org/10.1158/0008-5472.CAN-16-3011
Zhu YX, Shi CX, Bruins LA, Jedlowski P, Wang X, Kortüm KM et al. Loss of FAM46C promotes cell survival in myeloma. Cancer Research. 2017 Aug 15;77(16):4317-4327. https://doi.org/10.1158/0008-5472.CAN-16-3011
Zhu, Yuan Xiao ; Shi, Chang Xin ; Bruins, Laura A. ; Jedlowski, Patrick ; Wang, Xuewei ; Kortüm, K. Martin ; Luo, Moulun ; Ahmann, Jonathan M. ; Braggio, Esteban D ; Stewart, Alexander Keith. / Loss of FAM46C promotes cell survival in myeloma. In: Cancer Research. 2017 ; Vol. 77, No. 16. pp. 4317-4327.
@article{dfa4f1fae25c40bdb4647adea33f304d,
title = "Loss of FAM46C promotes cell survival in myeloma",
abstract = "FAM46C is one of the most recurrently mutated genes in multiple myeloma; however its role in disease pathogenesis has not been determined. Here we demonstrate that wild-type (WT) FAM46C overexpression induces substantial cytotoxicity in multiple myeloma cells. In contrast, FAM46C mutations found in multiple myeloma patients abrogate this cytotoxicity, indicating a survival advantage conferred by the FAM46C mutant phenotype. WT FAM46C overexpression downregulated IRF4, CEBPB, and MYC and upregulated immunoglobulin (Ig) light chain and HSPA5/BIP. Furthermore, pathway analysis suggests that enforced FAM46C expression activated the unfolded protein response pathway and induced mitochondrial dysfunction. CRISPR-mediated depletion of endogenous FAM46C enhanced multiple myeloma cell growth, decreased Ig light chain and HSPA5/BIP expression, activated ERK and antiapoptotic signaling, and conferred relative resistance to dexamethasone and lenalidomide treatments. Genes altered in FAM46C-depleted cells were enriched for signaling pathways regulating estrogen, glucocorticoid, B-cell receptor signaling, and ATM signaling. Together these results implicate FAM46C in myeloma cell growth and survival and identify FAM46C mutation as a contributor to myeloma pathogenesis and disease progression via perturbation in plasma cell differentiation and endoplasmic reticulum homeostasis.",
author = "Zhu, {Yuan Xiao} and Shi, {Chang Xin} and Bruins, {Laura A.} and Patrick Jedlowski and Xuewei Wang and Kort{\"u}m, {K. Martin} and Moulun Luo and Ahmann, {Jonathan M.} and Braggio, {Esteban D} and Stewart, {Alexander Keith}",
year = "2017",
month = "8",
day = "15",
doi = "10.1158/0008-5472.CAN-16-3011",
language = "English (US)",
volume = "77",
pages = "4317--4327",
journal = "Journal of Cancer Research",
issn = "0099-7013",
publisher = "American Association for Cancer Research Inc.",
number = "16",

}

TY - JOUR

T1 - Loss of FAM46C promotes cell survival in myeloma

AU - Zhu, Yuan Xiao

AU - Shi, Chang Xin

AU - Bruins, Laura A.

AU - Jedlowski, Patrick

AU - Wang, Xuewei

AU - Kortüm, K. Martin

AU - Luo, Moulun

AU - Ahmann, Jonathan M.

AU - Braggio, Esteban D

AU - Stewart, Alexander Keith

PY - 2017/8/15

Y1 - 2017/8/15

N2 - FAM46C is one of the most recurrently mutated genes in multiple myeloma; however its role in disease pathogenesis has not been determined. Here we demonstrate that wild-type (WT) FAM46C overexpression induces substantial cytotoxicity in multiple myeloma cells. In contrast, FAM46C mutations found in multiple myeloma patients abrogate this cytotoxicity, indicating a survival advantage conferred by the FAM46C mutant phenotype. WT FAM46C overexpression downregulated IRF4, CEBPB, and MYC and upregulated immunoglobulin (Ig) light chain and HSPA5/BIP. Furthermore, pathway analysis suggests that enforced FAM46C expression activated the unfolded protein response pathway and induced mitochondrial dysfunction. CRISPR-mediated depletion of endogenous FAM46C enhanced multiple myeloma cell growth, decreased Ig light chain and HSPA5/BIP expression, activated ERK and antiapoptotic signaling, and conferred relative resistance to dexamethasone and lenalidomide treatments. Genes altered in FAM46C-depleted cells were enriched for signaling pathways regulating estrogen, glucocorticoid, B-cell receptor signaling, and ATM signaling. Together these results implicate FAM46C in myeloma cell growth and survival and identify FAM46C mutation as a contributor to myeloma pathogenesis and disease progression via perturbation in plasma cell differentiation and endoplasmic reticulum homeostasis.

AB - FAM46C is one of the most recurrently mutated genes in multiple myeloma; however its role in disease pathogenesis has not been determined. Here we demonstrate that wild-type (WT) FAM46C overexpression induces substantial cytotoxicity in multiple myeloma cells. In contrast, FAM46C mutations found in multiple myeloma patients abrogate this cytotoxicity, indicating a survival advantage conferred by the FAM46C mutant phenotype. WT FAM46C overexpression downregulated IRF4, CEBPB, and MYC and upregulated immunoglobulin (Ig) light chain and HSPA5/BIP. Furthermore, pathway analysis suggests that enforced FAM46C expression activated the unfolded protein response pathway and induced mitochondrial dysfunction. CRISPR-mediated depletion of endogenous FAM46C enhanced multiple myeloma cell growth, decreased Ig light chain and HSPA5/BIP expression, activated ERK and antiapoptotic signaling, and conferred relative resistance to dexamethasone and lenalidomide treatments. Genes altered in FAM46C-depleted cells were enriched for signaling pathways regulating estrogen, glucocorticoid, B-cell receptor signaling, and ATM signaling. Together these results implicate FAM46C in myeloma cell growth and survival and identify FAM46C mutation as a contributor to myeloma pathogenesis and disease progression via perturbation in plasma cell differentiation and endoplasmic reticulum homeostasis.

UR - http://www.scopus.com/inward/record.url?scp=85028329844&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85028329844&partnerID=8YFLogxK

U2 - 10.1158/0008-5472.CAN-16-3011

DO - 10.1158/0008-5472.CAN-16-3011

M3 - Article

C2 - 28619709

AN - SCOPUS:85028329844

VL - 77

SP - 4317

EP - 4327

JO - Journal of Cancer Research

JF - Journal of Cancer Research

SN - 0099-7013

IS - 16

ER -